SiPhox Health: Albumin Testing at Home. Painless & Fast

The route publishes $124 and the homepage identifies additional shipping and handling, while membership pages describe cadence and cancellation. Refund limits after shipment and discretionary treatment of partial results create material terms tradeoffs, and the route-specific total cost and billing schedule are not confirmed.

Albumin coverage is directly named on the route and the route promises 20+ additional biomarkers. The exact additional list and route-to-panel mapping are missing, and official panel material shows that Albumin availability varies across selected panel and sex combinations.

The route connects Albumin tracking to personalized wellness insights and next steps, and the terms establish a non-diagnostic boundary. The page does not define a specific Albumin decision, clinical threshold, or action boundary, so relevance is useful for monitoring but not fully specified for clinical decisions.

The provider describes detailed analysis, personalized recommendations, an action plan, report scoring, and PDF export, with a wellness-only disclaimer. No Albumin-specific reference interval, report example, uncertainty detail, or defined follow-up rule was available in the reviewed official material.

The exact route identifies Albumin and the provider publishes claims about CLIA/CAP laboratory use, assay validation, and 95%-99% agreement with venous draws. Reliability remains bounded because the performing laboratory, assay method, Albumin-specific validation, and performance characteristics are not named in the reviewed official sources.

The product is presented as an at-home, no-referral workflow with upper-arm collection, live support, portal results, and a stated 7-10 day result window. Refrigeration, multiple-device use, and a same-day weekday physical FedEx handoff create practical constraints, and state availability is unresolved.

The provider publishes health-data rights and a privacy portal, but its terms authorize broad medical and personal information uses and disclosures for research, analytics, AI-related purposes, and anonymized or aggregated research sales. Retention, specimen handling, and detailed security controls remain unresolved.

Route identity, displayed price, collection approach, claimed timing, membership workflow, and policy links are public. Decision-critical gaps remain for the performing laboratory, assay method, exact panel mapping, state availability, total checkout cost, and consistent adjacent panel naming and counts.